Biocon has informed that it enclosed Company Statement with respect to ‘Biocon Secures Market Entry for Yesintek™, a Proposed Biosimilar to Stelara®, in Additional Global Markets’. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.